J J van den Broek1, F S W van der Wolf2, L A Heijnen3, W H Schreurs3. 1. Department of Surgery, Northwest clinics, PO box 501, 1815 JD, Alkmaar, The Netherlands. jorisvdbroek@gmail.com. 2. Department of Radiology, Antonius Hospital Sneek, Sneek, The Netherlands. 3. Department of Surgery, Northwest clinics, PO box 501, 1815 JD, Alkmaar, The Netherlands.
Abstract
BACKGROUND: MRI detected extramural vascular invasion (mrEMVI) is a poor prognostic factor in rectal cancer patients. The objectives of this study were to assess survival outcomes in patients with and without mrEMVI and to compare the prognostic value of mrEMVI with other rectal cancer features. METHODS: In a Dutch high volume rectal cancer center cohort of sixty-seven locally advanced rectal cancer patients, an independent radiologist reviewed all primary staging MRI scans. The presence of mrEMVI was correlated to tumor specific and survival outcomes. RESULTS: 20/67 patients had mrEMVI positive rectal cancer. 55% (11/20) developed metachronous metastases, compared with 23% (11/47) in the mrEMVI negative group (OR 4.0, p = 0.01). Overall survival was also decreased with a Hazard ratio of 3.3 (p = 0.01). A multivariable logistic regression with a backward selection procedure was conducted including cT-stage, c-N-stage, extramural tumor invasion depth, mesorectal fascia involvement, distance to anorectal junction, tumor length, mrEMVI, CEA level, and synchronous metastases. After stepwise removal based on p value, only positive mrEMVI remained as a single significant predictor for metachronous metastases (OR: 4.16 , p < 0.05). CONCLUSION: Positive mrEMVI is a poor prognostic factor in locally advanced rectal cancer with a 4-fold increased risk of developing metachronous metastases after surgery and a worsened overall survival. mrEMVI also appeared an independent risk factor, with a stronger prediction for metachronous metastases than other MRI-detectable tumor characteristics. mrEMVI should be incorporated in all risk stratification guidelines for rectal cancer.
BACKGROUND: MRI detected extramural vascular invasion (mrEMVI) is a poor prognostic factor in rectal cancerpatients. The objectives of this study were to assess survival outcomes in patients with and without mrEMVI and to compare the prognostic value of mrEMVI with other rectal cancer features. METHODS: In a Dutch high volume rectal cancer center cohort of sixty-seven locally advanced rectal cancerpatients, an independent radiologist reviewed all primary staging MRI scans. The presence of mrEMVI was correlated to tumor specific and survival outcomes. RESULTS: 20/67 patients had mrEMVI positive rectal cancer. 55% (11/20) developed metachronous metastases, compared with 23% (11/47) in the mrEMVI negative group (OR 4.0, p = 0.01). Overall survival was also decreased with a Hazard ratio of 3.3 (p = 0.01). A multivariable logistic regression with a backward selection procedure was conducted including cT-stage, c-N-stage, extramural tumor invasion depth, mesorectal fascia involvement, distance to anorectal junction, tumor length, mrEMVI, CEA level, and synchronous metastases. After stepwise removal based on p value, only positive mrEMVI remained as a single significant predictor for metachronous metastases (OR: 4.16 , p < 0.05). CONCLUSION: Positive mrEMVI is a poor prognostic factor in locally advanced rectal cancer with a 4-fold increased risk of developing metachronous metastases after surgery and a worsened overall survival. mrEMVI also appeared an independent risk factor, with a stronger prediction for metachronous metastases than other MRI-detectable tumor characteristics. mrEMVI should be incorporated in all risk stratification guidelines for rectal cancer.
Entities:
Keywords:
EMVI; MRI; Prognosis; extramural vascular invasion; rectal cancer
Authors: Min Soo Cho; Youn Young Park; Jiho Yoon; Seung Yoon Yang; Seung Hyuk Baik; Kang Young Lee; Ik Yong Kim; Nam Kyu Kim Journal: J Surg Oncol Date: 2018-05-22 Impact factor: 3.454
Authors: Chris J Hunter; Aurelie Garant; Té Vuong; Giovanni Artho; Robert Lisbona; Paris Tekkis; Muti Abulafi; Gina Brown Journal: Ann Surg Oncol Date: 2011-09-13 Impact factor: 5.344
Authors: Joris J van den Broek; Floor S W van der Wolf; Max J Lahaye; Luc A Heijnen; Christof Meischl; Martin A Heitbrink; W Hermien Schreurs Journal: Dis Colon Rectum Date: 2017-03 Impact factor: 4.585
Authors: Muhammed R S Siddiqui; Constantinos Simillis; Chris Hunter; Manish Chand; Jemma Bhoday; Aurelie Garant; Te Vuong; Giovanni Artho; Shahnawaz Rasheed; Paris Tekkis; Al-Mutaz Abulafi; Gina Brown Journal: Br J Cancer Date: 2017-04-27 Impact factor: 7.640